Genmab shares jumped to record highs after results suggested a recently acquired cancer medicine could become a new standard for a form of head-and-neck cancer. The stock move reflects investor expectations that the trial data are not just positive, but potentially practice-changing within the relevant patient population. The coverage attributes the surge to data indicating improved outcomes versus existing approaches, with Genmab’s market value rising by more than $7 billion. The report frames the findings as advancing the medicine toward broader uptake, pending the usual regulatory and confirmatory steps. For biotech investors and pipeline strategists, the episode is a reminder that acquisitions can quickly re-rate programs when clinical signals emerge from late-stage or pivotal data. —